Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.61 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14871034 | 0.92 | MEN1 (0.63) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL20188098 | 0.90 | HPGD (0.65) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL22015905 | 0.90 | HPGD (0.65) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL28242074 | 0.87 | HPGD (0.61) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3898465 | 0.87 | HPGD (0.61) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL20187714 | 0.86 | HPGD (0.59) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3900474 | 0.86 | SIRT2 (0.60) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL6678636 | 0.85 | SMN1; SMN2 (0.67) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL6593564 | 0.85 | MEN1 (0.55) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL3457437 | 0.85 | HPGD (0.55) | MEN1KMT2AALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECH CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4626880-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | Shanghai Degron Biomedical Technology Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| US-12264120-B2 | Amine synergists with UV—a absorption | SUN CHEMICAL CORPORATION (US) | 2025-04-01 | — | — | US | disclosed |
| EP-4301725-B1 | AMINE SYNERGISTS WITH UV-A ABSORPTION | SUN CHEMICAL CORP (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240270678-A1 | AMINE SYNERGISTS WITH UV-A ABSORPTION | SUN CHEMICAL CORPORATION (US) | 2024-08-15 | — | — | US | disclosed |
| WO-2024114639-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| EP-4301725-A1 | AMINE SYNERGISTS WITH UV-A ABSORPTION | Sun Chemical Corporation (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023118482-A1 | AMINE SYNERGISTS WITH UV-A ABSORPTION | SUN CHEMICAL CORPORATION (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023097386-A1 | SELECTIVE HDAC6-INHIBITING N-ACYLHYDRAZONE COMPOUNDS, METHODS FOR PRODUCING SAME, COMPOSITIONS, USES, TREATMENT METHODS AND KITS | EUROFARMA LABORATÓRIOS S.A (BR) | 2023-06-08 | — | — | WO | disclosed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004037799-A1 | IMPROVEMENT IN THE STORAGE STABILITY OF PHOTOINITIATORS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-05-06 | — | — | WO | disclosed |
| US-6689882-B2 | REACTING A MORPHOLINE WITH A SUBSTITUTED BENZENE, WHEREIN MORPHOLINE IS USED AS A REACTANT AND AS THE ONLY ONE SOLVENT | ASTRAZENECA AB (SE) | 2004-02-10 | — | — | US | disclosed |
| US-20030171581-A1 | Process for the synthesis of morpholinylbenzenes | ASTRAZENECA AB (SE) | 2003-09-11 | — | — | US | disclosed |
| CN-1429216-A | A new process for synthesis of morpholinylbenzenes | ASTRAZENECA AB (SE) | 2003-07-09 | — | — | CN | disclosed |
| EP-1286977-A1 | A NEW PROCESS FOR THE SYNTHESIS OF MORPHOLINYLBENZENES | AstraZeneca AB (SE) | 2003-03-05 | — | — | EP | disclosed |
| WO-2002059132-A1 | INTERMEDIATE COMPOUNDS USEFUL FOR MAKING ANTIVIRAL COMPOUNDS | VIROPHARMA INCORPORATED (US) | 2002-08-01 | — | — | WO | disclosed |
| WO-2001087865-A1 | A NEW PROCESS FOR THE SYNTHESIS OF MORPHOLINYLBENZENES | ASTRAZENECA AB (SE) | 2001-11-22 | — | — | WO | disclosed |
| CN-1271279-A | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LTD (GB) | 2000-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12264120-B2 | Amine synergists with UV—a absorption | OR51E2, PNMT, ALDH7A1 | MEN1 481/4885KMT2A 1548/4885ALDH1A1 11/4885 |
| US-20240270678-A1 | AMINE SYNERGISTS WITH UV-A ABSORPTION | ALDH7A1, PNMT, OR51E2 | MEN1 601/4885KMT2A 1208/4885ALDH1A1 8/4885 |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | PEPD, TFPI, F2 | MEN1 505/4885KMT2A 1633/4885ALDH1A1 3153/4885 |
| US-20030171581-A1 | Process for the synthesis of morpholinylbenzenes | CYP1B1, TBCB, MAP1B | MEN1 362/4885KMT2A 1790/4885ALDH1A1 1548/4885 |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | ELAVL1, ELAVL3, HNRNPL | MEN1 1990/4885KMT2A 3940/4885ALDH1A1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.